R&D News | pharmaphorum

News

UK pharma struggling to recruit digital talent, says ABPI

The life sciences industry in the UK is embracing digitalisation, but that is creating a demand for workers with artificial intelligence and data skills that is outstrippi

News

Kate helps Astellas double up on XLMTM gene therapy

Astellas’ gene therapy for rare disease X-linked myotubular myopathy (XLMTM) has been hampered by safety concerns, so its decision to license an alternative from start-up

News

GSK claims first EU approval for an RSV vaccine

GSK’s Arexvy has become the first vaccine for respiratory syncytial virus (RSV) to be approved in the EU, getting the nod from the European Commission for use in older adu

News

ASCO: AI-powered MOSAIC will build 3D atlas for cancer

In amongst the big clinical trial readouts at ASCO, a new research project made its official debut with the ambitious goal of mapping cancer cells’ interactions with their

News

ASCO: Enhertu data sets up tumour-agnostic label bid

AstraZeneca and Daiichi Sankyo’s Enhertu is already gathering momentum as a treatment for HER2-positive and HER2-low breast, gastric, and lung cancer, but new data could b

News

ASCO: Moderna, Merck melanoma vaccine set for phase 3

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase

UK pharma struggling to recruit digital talent, says ABPI

Kate helps Astellas double up on XLMTM gene therapy

GSK claims first EU approval for an RSV vaccine

ASCO: AI-powered MOSAIC will build 3D atlas for cancer

ASCO: Enhertu data sets up tumour-agnostic label bid

ASCO: Moderna, Merck melanoma vaccine set for phase 3

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks